Induction FLOT Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in the Treatment of Lower Esophageal and Proximal Gastric Adenocarcinoma: A Phase II, Single-Arm Clinical Trial.
J Gastrointest CancerSep 15, 2026 (epub)
Clinical ResearchOncology (Medical)GastroenterologyGeneral SurgeryPathology (Anatomic & Clinical)Open access
Seyed Amir Aledavood, Zohreh Pishevar, Kazem Anvari et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II, single-arm clinical trial evaluated the effectiveness of induction FLOT chemotherapy followed by neoadjuvant chemoradiotherapy in patients with resectable distal esophageal and proximal gastric adenocarcinoma. Among 57 enrolled patients, 40 underwent surgical resection, with a complete pathological response observed in 27.5% of those evaluated.
Key findings
- Complete pathological response was achieved in 27.5% of patients who underwent surgical resection.
- Induction FLOT chemotherapy was administered to all patients, with 89.5% completing both cycles.
- 73.6% of patients received more than four cycles of concurrent chemoradiotherapy.
Why it matters
The study suggests that early initiation of systemic therapy with induction FLOT may enhance treatment outcomes in patients with advanced adenocarcinoma of the esophagus and stomach, potentially improving survival rates.